Cerebral gliomas have a poor survival time even after multimodal treatment, 
because of the unavoidable recurrence of tumor. Several trials with a 
combination of old and new chemotherapics have been performed, but survival time 
remains generally less than 12 months. Tamoxifen (TAM) has recently been shown 
to inhibit the growth rate of established and low-passage human glioma cell 
lines. Furthermore, this drug has enabled stabilization of the clinical and 
radiographic picture in selected patients with recurrent glioma. Here we review 
published data to discuss a potential role of TAM in the multimodal 
postoperative treatment of cerebral gliomas.